Serina Therapeutics appoints Dr. Jay Venkatesan to board; Dr. Milton Harris becomes Director Emeritus

Serina Therapeutics, Inc.

Dr. Jay Venkatesan appointed to Board effective Feb 12, 2025; will serve as Audit Committee Chair and on Nominating/Governance Committee.
Venkatesan previously co-founded Alpine Immune Sciences (acquired by Vertex for $4.9B) and served as CEO of Angion Biomedica.
Dr. Milton Harris departs board effective Feb 11, 2025, becomes Director Emeritus and Chair of Scientific Advisory Board.
Harris is co-founder, instrumental in POZ Platform; departure not due to any disagreement.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Jay Venkatesan

Director

SER · Serina Therapeutics, Inc.

Effective: 2025-02-12
Filed: February 12, 2025, 6:59 PM ET

On February 11, 2025 , the Board of Directors of Serina Therapeutics, Inc. (the “Company”) appointed Dr. Jay Venkatesan to the Company’s Board of Directors, effective February 12, 2025.

Departed

Dr. Milton Harris

Director

SER · Serina Therapeutics, Inc.

Effective: 2025-02-11
Filed: February 12, 2025, 6:59 PM ET

The Company also announced the departure of Dr. Milton Harris from its Board of Directors effective February 11, 2025 .

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Jay Venkatesan was appointed as Director at Serina Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On February 11, 2025 , the Board of Directors of Serina Therapeutics, Inc. (the “Company”) appointed Dr. Jay Venkatesan to the Company’s Board of Directors, effective February 12, 2025.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Milton Harris departed as Director at Serina Therapeutics, Inc..

Action: departed
Role: Director

Exact text from the filing

The Company also announced the departure of Dr. Milton Harris from its Board of Directors effective February 11, 2025 .

View on SEC.gov

Serina Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001708599-25-000016

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.